PTSD Differential Diagnosis: A Comprehensive Guide for Clinicians

Posttraumatic stress disorder (PTSD) is a significant mental health condition that develops after exposure to a traumatic event. It is characterized by a wide range of symptoms affecting various aspects of life, including cognition, mood, physical sensations, and behavior. These symptoms can lead to chronic impairment, increase the risk of other psychiatric disorders, and elevate suicide risk. For healthcare professionals, accurately diagnosing PTSD is crucial, and understanding the Ptsd Differential Diagnosis is essential to distinguish it from other conditions with overlapping symptoms.

This article aims to provide a comprehensive overview of PTSD, with a particular focus on PTSD differential diagnosis. It will delve into the complexities of diagnosing PTSD, differentiating it from conditions with similar presentations, and ensuring accurate identification for effective management. This resource is designed for clinicians seeking to enhance their understanding of PTSD and improve their diagnostic acumen in this challenging area.

Objectives:

• Understand the DSM-5-TR diagnostic criteria for PTSD and their application in clinical practice.
• Master the PTSD differential diagnosis by recognizing the nuances in symptomatology and distinguishing PTSD from similar psychiatric disorders.
• Learn evidence-based therapeutic interventions for PTSD, including psychological and pharmacological approaches, tailored to individual patient needs.
• Foster interdisciplinary collaboration to enhance care coordination and improve outcomes for patients with PTSD, emphasizing accurate diagnosis and differential diagnosis.

Introduction

Posttraumatic stress disorder (PTSD) is a prevalent psychiatric disorder that arises following an individual’s experience of a traumatic event. The clinical presentation of PTSD is broad, encompassing symptoms that impair cognition, mood, somatic experiences, and behavior. These symptoms can result in chronic functional impairments, increase the likelihood of comorbid psychiatric illnesses, and elevate the risk of suicide.[1] Accurate diagnosis is paramount, and a thorough understanding of PTSD differential diagnosis is crucial for clinicians.

PTSD was officially recognized in the Diagnostic and Statistical Manual of Mental Disorders (DSM) 3rd edition in 1980.[2] This inclusion marked a significant step in acknowledging the profound impact of traumatic experiences on mental health. The DSM criteria for PTSD center on exposure to a traumatic event followed by specific symptom clusters: intrusive memories, avoidance behaviors, negative alterations in cognition and mood, and hyperarousal. Understanding these criteria is the first step in PTSD differential diagnosis. Effective management of PTSD is complex and requires individualized approaches, considering the unique nature of each trauma and the variability in symptom presentation. Prevention and treatment strategies involve both psychological interventions and pharmacotherapy.[3][4][5] A key aspect of successful intervention is the ability to perform an accurate PTSD differential diagnosis to rule out or address comorbid conditions.

Etiology

While not everyone who experiences trauma develops long-term mental health issues, trauma exposure is a defining characteristic for the development of PTSD, according to the DSM-5-TR. Trauma, in the context of PTSD, is defined as exposure to actual or threatened death, serious injury, or sexual violence. This can include direct experience, witnessing trauma happening to others, or learning about trauma experienced by a close person.[6] Understanding the nature of trauma is essential when considering the PTSD differential diagnosis, as different types of trauma may lead to varying symptom presentations.

Several psychological theories attempt to explain how trauma leads to PTSD. Janoff-Bulman’s shattered assumptions theory (1992) proposes that trauma can fundamentally alter an individual’s core beliefs about themselves and the world. These pre-trauma assumptions often include beliefs like “the world is benevolent,” “the world is meaningful,” and “the self is worthy.” Traumatic events can weaken or “shatter” these foundational beliefs.[7] This theory helps in understanding the negative alterations in cognition and mood seen in PTSD, which are crucial for PTSD differential diagnosis.

Psychodynamic psychology emphasizes the role of past experiences in shaping current psychological forces influencing behavior and emotions.[8] While Jean-Martin Charcot’s 1890 assertion that psychological trauma is the root of all mental illness has been disproven, the profound impact of trauma, especially early life trauma, on mental health development is well-recognized.[9] From a psychodynamic perspective, PTSD can be related to unconscious trust issues. Trauma survivors may struggle to trust in the safety of the world or the reliability of others to avoid causing harm.[10] These trust issues can manifest in ways that overlap with other disorders, highlighting the importance of PTSD differential diagnosis.

Behavioral science offers insights into trauma’s impact on cognition through the concept of conditioned fear responses. Exposure to a significant stimulus, often the traumatic event itself, can lead to learned fear. Repeated trauma, such as in cases of domestic or parental abuse, can reinforce this conditioned response.[11] Understanding conditioned fear responses is vital for designing effective therapies and for differentiating PTSD from anxiety disorders in the PTSD differential diagnosis.

Social support systems play a critical role in modulating PTSD risk after trauma. Strong social support can decrease the likelihood of developing PTSD, while isolation or poor social support increases the risk of acute stress disorder and PTSD.[12] Other factors that increase PTSD risk include lower education, lower socioeconomic status, childhood adversity, gender, race, physical injury (including traumatic brain injury), and the initial severity of reaction to the trauma.[13][14][15][16][17] These risk factors are important to consider when assessing patients and formulating a PTSD differential diagnosis.

Epidemiology

The lifetime prevalence of PTSD in the United States and Canada ranges from 6.1% to 9.2% in the general adult population, with 1-year prevalence rates between 3.5% and 4.7%.[18][13][19][20][[21]](#article-27568.r21] Certain populations in the Western Hemisphere, such as indigenous peoples and refugees, exhibit higher PTSD prevalence.[22][23][[13]](#article-27568.r13] Lower prevalence rates have been observed outside the Western Hemisphere, though the reasons remain unclear.[24] Epidemiological data provides context for understanding the scope of PTSD and its potential prevalence in different patient populations, which is relevant for PTSD differential diagnosis in diverse clinical settings.

Intentional trauma is more strongly associated with PTSD than accidental or nonviolent trauma.[25][26] Repeated and prolonged trauma exposure also increases PTSD risk.[27] While both males and females develop PTSD, females are more predisposed, with variations based on the type of trauma.[28] These factors related to trauma type and demographics are important considerations when evaluating patients and performing a PTSD differential diagnosis.

Pathophysiology

The pathophysiology of PTSD begins with the body’s initial response to trauma, characterized by a surge of adrenaline from sympathetic nervous system activation. This physiological response can lead to tachycardia, elevated blood pressure, and neuroendocrine responses like cortisol and catecholamine release.[29] Prolonged or repeated trauma stimuli can result in a conditioned behavioral response, potentially leading to acute stress disorder or PTSD. Understanding the physiological responses helps in comprehending the somatic symptoms of PTSD, which is relevant to PTSD differential diagnosis.

Neuroanatomically, the amygdala plays a key role in threat detection and fear response. MRI studies on individuals with PTSD have shown inconsistent findings, including reduced total brain volume.[30][[31]](#article-27568.r31] The amygdala, an evolutionarily ancient brain structure, is primarily activated but usually regulated by the frontal cortex as cognitive and learned behaviors develop.[32] In PTSD patients, this frontal lobe regulation of the amygdala is dysregulated compared to those without PTSD. This dysregulation might partially explain the reduced brain volume observed in chronic PTSD. Neurotransmitter levels, including serotonin, dopamine, epinephrine, norepinephrine, glutamate, and GABA, have been studied in PTSD.[33] Although findings are inconsistent, neurotransmitter imbalances form the basis for psychopharmacological treatments.[34] While neuroimaging and neurotransmitter studies are primarily research tools, understanding these biological underpinnings enhances the clinical understanding of PTSD, aiding in PTSD differential diagnosis by considering the biological plausibility of symptoms.

History and Physical

The clinical presentation of PTSD varies greatly in both illness history and symptom presentation. Trauma types are diverse, and risks for specific traumas depend on patient characteristics like age, gender, location, family status, and physical disabilities.[35] Trauma can include sexual assault, mass conflict and displacement (refugee status), military combat, physical injury, and medical illness.[17] A thorough understanding of individual patient backgrounds and social history is crucial. Adult PTSD patients often present with symptoms stemming from childhood trauma, which may be temporally distant from the clinical evaluation.[36] The duration of symptoms since the traumatic event is a key factor distinguishing PTSD from other conditions, such as acute stress disorder.[37] A detailed history, including trauma history and symptom timeline, is essential for accurate PTSD differential diagnosis.

Dissociative symptoms may occur in PTSD and must be differentiated from pre-existing dissociative disorders. Dissociative symptoms include:

• Depersonalization: Feeling detached from one’s body, feeling “lost” or “floating above my body.”
• Derealization: Feeling that the surrounding world is unreal, like observing from a dreamlike state.[38]

Identifying and distinguishing dissociative symptoms is a critical aspect of PTSD differential diagnosis, particularly when considering dissociative disorders.

Discussing trauma requires a sensitive approach.[39] In cases of sexual assault, provider and patient gender should be considered, as survivors may struggle to be alone with someone of the same gender as their perpetrator. Some patients can discuss trauma easily, while others cannot without experiencing acute symptoms. Respecting patient boundaries and asking about their preferred level of detail is crucial, reflecting trauma-informed care principles.[39] Specific trauma details are usually not necessary for PTSD diagnosis, but are needed for certain psychotherapies, requiring patient consent. General symptom-related questions are optimal for initial diagnostic interviews to build rapport.[40] General questions can include:

• Do you think about the traumatic event more than you want to?
• Do you have nightmares or flashbacks related to the trauma?
• Do you avoid people or triggers associated with the trauma?
• Are you struggling with persistent sadness?

The mental status examination (MSE) is vital in assessing PTSD.[41] MSE findings can vary but may include:

• Appearance: Scars, wounds, or deformities from past trauma.
• Attitude and Behavior: Hypervigilance, observed eye contact.
• Affect: Fearful, anxious, apathetic, or depressed affect; range of affect, constricted affect (numbness).
• Thought content: Suicidal ideation, self-harm behaviors.
• Thought process: Non-linear thought processes, persistent negative beliefs.
• Insight: Fair understanding of illness, potential minimization of symptoms, difficulty connecting PTSD to comorbidities (depression, substance use, borderline personality disorder).
• Judgment: Assessed based on presentation and rational treatment decisions.[42]

Physical examination findings in PTSD are typically nonspecific. While primarily a psychiatric condition, some may exhibit physical symptoms of hyperarousal or chronic stress, such as increased heart rate, elevated blood pressure, muscle tension, and sleep disruption. These findings may be more pronounced during trauma recall or flashbacks. When prescribing medications for PTSD that affect blood pressure (clonidine, prazosin, venlafaxine), blood pressure monitoring is essential.[43] The MSE and physical exam provide valuable data points that, while not definitive for PTSD differential diagnosis alone, contribute to the overall clinical picture and help rule out other medical conditions.

Evaluation

Psychiatric evaluation is the cornerstone of PTSD diagnosis. Validated rating scales can aid screening and diagnosis, especially where psychiatric specialists are unavailable. Self-report scales include the PTSD Checklist for DSM-5 (PCL-5) and Trauma Symptom Checklist-40 (TSC-40).[44][45] The Clinician-Administered PTSD Scale (CAPS-5) is a 30-item structured interview.[46] These tools can support the diagnostic process and help in PTSD differential diagnosis by quantifying symptom severity.

Formal PTSD diagnosis requires meeting DSM-5-TR criteria. This involves a comprehensive evaluation using personal history, collateral information, and MSE to assess symptoms, functioning, and overall presentation against diagnostic criteria. The DSM-5-TR criteria, applicable to adults and children over 6 years (with a preschool subtype for younger children), are detailed below. A careful application of these criteria is fundamental to accurate PTSD differential diagnosis.

Posttraumatic Stress Disorder DSM-5-TR Criteria

Criterion A: Stressor

Exposure to actual or threatened death, serious injury, or sexual violence in 1 or more of the following ways:

1. Direct exposure to the traumatic event
2. Witnessing the trauma as it occurred to someone else
3. Learning that the traumatic event occurred to a close family relative or close friend in cases of actual or threatened trauma, accidental or violent death
4. Indirect exposure to aversive details of the traumatic event, usually in the course of professional duties (e.g., first responders, collecting human remains). This does not include exposure through media unless work-related.

Criterion B: Intrusion Symptoms

Presence of 1 or more of the following symptoms related to the traumatic event, beginning after the trauma:

1. Recurrent, involuntary, and intrusive distressing memories of the traumatic event. In children older than 6, this may manifest as repetitive play reenacting trauma aspects.
2. Distressing dreams related to the traumatic event. These may be repetitive; children may have frightening dreams, content may or may not be recognizable.
3. Dissociative reactions (e.g., flashbacks) where the individual feels or acts as if the traumatic event is recurring. Can range from brief reactions to complete loss of awareness. Children may reenact events in play.
4. Intense or prolonged psychological distress at exposure to cues resembling the traumatic event.
5. Marked physiological reactions to reminders of the traumatic event (e.g., increased heart rate).

Criterion C: Avoidance

Persistent avoidance of stimuli associated with the traumatic event, evidenced by 1 or both:

1. Avoidance of or attempts to avoid distressing memories, thoughts, or feelings about or closely associated with the traumatic event.
2. Avoidance of or attempts to avoid external reminders (people, places, activities, objects, situations) that arouse distressing memories, thoughts, or feelings about or closely associated with the traumatic event.

Criterion D: Negative Alterations in Cognition and Mood

Negative alterations in cognition and mood associated with the traumatic event, beginning or worsening after the traumatic event, evidenced by 2 or more:

1. Inability to remember an important aspect of the traumatic event (typically dissociative amnesia; not due to head injury, alcohol, or drugs).
2. Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world (e.g., “I am bad,” “The world is completely dangerous”).
3. Persistent distorted cognitions about the cause or consequences of the traumatic event that lead the individual to blame themselves or others.
4. Persistent negative emotional state (e.g., fear, horror, anger, guilt, or shame).
5. Markedly diminished interest or participation in significant activities.
6. Feelings of detachment or estrangement from others.
7. Persistent inability to experience positive emotions (e.g., happiness, satisfaction, or love).

Criterion E: Alterations in Arousal and Reactivity

Marked alterations in arousal and reactivity associated with the traumatic event, beginning or worsening after the traumatic event, evidenced by 2 or more:

1. Irritable behavior and angry outbursts (typically with little or no provocation), expressed as verbal or physical aggression toward people or objects.
2. Reckless or self-destructive behavior.
3. Hypervigilance.
4. Exaggerated startle response.
5. Problems with concentration.
6. Sleep disturbance (e.g., difficulty falling or staying asleep or restless sleep).

Criterion F: Duration

Persistence of symptoms in Criteria B, C, D, and E for more than 1 month.

Criterion G: Functional Significance

The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Criterion H: Exclusion

The disturbance is not attributable to the physiological effects of a substance (e.g., medication, alcohol) or another medical condition. [47]

Specifiers:

• Delayed Expression: Full diagnostic criteria are not met until at least 6 months after the trauma, although symptom onset may occur sooner.
• Dissociative Symptoms: Presence of persistent or recurrent symptoms of depersonalization and/or derealization. This specifier is associated with higher rates of childhood trauma, symptom severity, functional impairment, comorbidity, and suicidality.

These DSM-5-TR criteria provide a structured framework for diagnosing PTSD and are essential for guiding the PTSD differential diagnosis process.

Treatment / Management

PTSD treatment requires a patient-centered approach, with informed consent for all interventions. Many PTSD patients are hesitant to seek treatment, and some exhibit treatment-resistant symptoms. A combination of medication and therapy may be necessary, but patients should be offered a choice between modalities. Therapy is generally preferred initially, but patients with severe symptoms or comorbidities may benefit from starting with medication to stabilize before engaging in therapy. Choosing the right treatment approach is often informed by the PTSD differential diagnosis, as comorbid conditions may influence treatment selection.

Psychotherapeutic Approaches

Trauma-focused psychotherapy is the recommended first-line treatment for PTSD, including cognitive behavioral therapy (CBT), exposure-based therapy, and eye movement desensitization and reprocessing (EMDR).[3][48][49][50] Studies show trauma-focused psychotherapy leads to greater symptom improvement compared to no treatment.[3] Therapy may also yield slightly better outcomes than pharmacotherapy.[51][48] When considering PTSD differential diagnosis, it is important to note that psychotherapy can also address comorbid conditions.

CBT techniques help identify and modify maladaptive beliefs that develop post-trauma. Specific techniques include psychoeducation, relaxation exercises, coping skills training, and stress management.[52]

Exposure therapy, commonly used for anxiety disorders, applies learning principles to PTSD by gradually reintroducing trauma-related stimuli to extinguish conditioned fear responses. It requires patient consent, is not suitable for all cases, and demands significant patient effort.[53]

EMDR was developed after observing that saccadic eye movements can reduce the intensity of disturbing thoughts. Voluntary eye movements while focusing on distressing memories can reduce associated anxiety. EMDR has been shown to desensitize traumatic memories and enhance positive self-beliefs in PTSD patients.[54][55] The exact neural mechanisms of EMDR are still being investigated.[56]

Supportive psychotherapy can be beneficial for individuals experiencing acute trauma or acute stress disorder.[57] These psychotherapeutic approaches are crucial components of PTSD management, and their selection may be influenced by the PTSD differential diagnosis, particularly when comorbid anxiety or depressive disorders are present.

Medication Approaches

Selective serotonin reuptake inhibitors (SSRIs) like sertraline and paroxetine are FDA-approved for PTSD treatment. Other SSRIs and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) are often used off-label. SSRIs are more effective than placebo in reducing PTSD symptoms, but evidence does not strongly differentiate specific SSRIs or SNRIs in efficacy.[4][5][58] Pharmacotherapy plays a vital role in PTSD management, especially when considering PTSD differential diagnosis and addressing comorbid conditions like major depressive disorder.

Off-label medications are commonly used for sleep disturbances or nightmares associated with PTSD. Prazosin, an alpha-adrenergic receptor inhibitor, is frequently used alone or with SSRIs. It is hypothesized to reduce nightmares by toning down sympathetic nervous system activity. However, prazosin efficacy for nightmares has mixed and inconsistent findings.[59][60][[61]](#article-27568.r61] Clonidine is also occasionally used for similar purposes. Blood pressure monitoring is important for patients on these medications, and abrupt cessation should be avoided to prevent rebound hypertension.

Second-generation antipsychotics are less commonly used off-label for PTSD, but may be helpful for comorbid psychotic symptoms or treatment-resistant depression (where antipsychotics augment SSRIs). Quetiapine has shown efficacy as monotherapy for PTSD in military veterans.[62] Other antipsychotics have yielded limited and mixed results in PTSD populations.[63][64][65] Pharmacological interventions must be carefully considered, especially in the context of PTSD differential diagnosis, to address comorbid conditions and target specific symptom clusters.

Novel Approaches

In 2020, the FDA cleared a class II medical device utilizing smartwatch technology to monitor heart rate during sleep in PTSD patients to correlate physiological responses (biofeedback) with PTSD-related nightmares.[66] Emerging technologies like biofeedback offer promising adjunctive treatments for PTSD, though their role in PTSD differential diagnosis is indirect, primarily focusing on symptom management.

Differential Diagnosis

The PTSD differential diagnosis includes several conditions with overlapping symptoms.

Acute Stress Disorder

PTSD and acute stress disorder share significant symptom overlap. The key differentiating factor is symptom duration; acute stress disorder is diagnosed when symptoms last less than one month.[37] Distinguishing between these two conditions based on symptom duration is a primary step in PTSD differential diagnosis.

Dissociative Disorders

Primary dissociative disorders include dissociative identity disorder (DID), dissociative amnesia, and depersonalization/derealization disorder. DID involves identity disruption with two or more distinct personality states. Dissociative amnesia is characterized by inability to recall autobiographical information, often trauma-related, but without other PTSD symptoms. Depersonalization/derealization disorder shares dissociative symptoms with PTSD but lacks other PTSD criteria.[67] Careful assessment of dissociative symptoms and other PTSD criteria is crucial in the PTSD differential diagnosis to differentiate PTSD from primary dissociative disorders.

Major Depressive Disorder

Affective changes are common in PTSD, and major depressive disorder (MDD) can be comorbid. MDD diagnosis requires at least one major depressive episode, defined by persistent decreased mood for at least two weeks.[68] While mood symptoms overlap, a thorough PTSD differential diagnosis must distinguish between PTSD-related mood changes and MDD, especially when considering comorbidity.

Adjustment Disorder

Adjustment disorder involves emotional or behavioral symptoms in response to an identifiable stressor (not necessarily trauma), beginning within three months of the stressor and not persisting beyond six months after the stressor ceases. Symptoms not meeting these criteria may indicate a more chronic psychiatric diagnosis.[69] The nature of the stressor and symptom duration help differentiate adjustment disorder from PTSD in the PTSD differential diagnosis.

Other Psychiatric Disorders

PTSD symptom duration is variable. Patients may improve over time and no longer meet PTSD criteria. However, they may still experience other psychiatric disorders. Patients with a history of PTSD may mistakenly attribute current symptoms to resolved PTSD even when they no longer meet diagnostic criteria. Clinicians should assess whether PTSD is current, improved, resolved, or comorbid with other psychiatric disorders.[70] A comprehensive PTSD differential diagnosis should always consider the possibility of comorbid psychiatric conditions and rule out other disorders that may better explain the patient’s current presentation.

Prognosis

PTSD outcomes are highly variable due to numerous factors. Patients who engage in PTSD treatments generally have better outcomes than those who do not.[3][4][5] Chronic PTSD is common, with estimates suggesting that one-third of patients still have symptoms one year after diagnosis, and another third still have symptoms after ten years.[26] Understanding the prognosis of PTSD and the factors influencing recovery is important for patient education and management, though less directly relevant to PTSD differential diagnosis.

Positive psychology emphasizes psychological resilience and posttraumatic growth after trauma.[71] Posttraumatic growth describes positive changes in self-perception, relationships, and life philosophy following trauma recovery, potentially leading to increased self-awareness, self-confidence, and appreciation for life.[72] While posttraumatic growth is desirable, it is not guaranteed and may be uncommon. Research on positive psychology applications in trauma disorders is ongoing and limited.[73][74] While prognosis and posttraumatic growth are important aspects of PTSD, they are not directly involved in PTSD differential diagnosis.

Complications

PTSD symptoms, even when resolved, can lead to psychiatric comorbidity. Trauma is a known risk factor for MDD, borderline personality disorder, anxiety disorders, substance use disorders, psychotic disorders, and more.[75] PTSD patients have increased suicide risk and should be regularly screened for suicidal ideation.[1] Individuals with PTSD are more likely to experience occupational problems and disability.[[76]](#article-27568.r76] Those with sexual trauma history report more intimate relationship problems.[77][76] Understanding potential complications of PTSD, including comorbidity, reinforces the importance of accurate PTSD differential diagnosis to address all aspects of a patient’s mental health.

Deterrence and Patient Education

PTSD deterrence and prevention focus on minimizing trauma impact and mitigating persistent psychological distress. Primary prevention involves promoting resilience, coping skills, and social support to enhance stress coping abilities. Clinician awareness of at-risk populations is crucial for early detection. Military personnel and veterans should be systematically screened for PTSD.[78] Primary care providers should be alert to patients presenting with new anxiety, fear, and insomnia potentially related to trauma.[79] Community education on trauma-informed practices and early intervention can reduce trauma risk and its effects. Prevention and early detection efforts are important in reducing PTSD incidence, though not directly related to PTSD differential diagnosis.

Secondary prevention emphasizes timely interventions for high-risk individuals to prevent symptom escalation. Integrating trauma-focused mental health awareness into education, healthcare, and emergency services is vital for a culture of prevention and support. By addressing risk factors and promoting resilience, the goal is to reduce PTSD incidence and severity, improving mental health outcomes. While prevention is crucial, the focus of this article remains on PTSD differential diagnosis for clinicians managing existing cases.

Enhancing Healthcare Team Outcomes

PTSD is a common and complex condition requiring a collaborative, patient-centered approach. Patients benefit from psychiatric specialist referral when available, but screening tools are accessible for all clinicians. Physicians, advanced practitioners, nurses, pharmacists, therapists, social workers, and other healthcare professionals play essential roles in enhancing PTSD care. Accurate PTSD differential diagnosis is a shared responsibility across the healthcare team.

Proficiency in trauma-informed care and evidence-based interventions is crucial. Clinicians should be skilled in comprehensive assessments, differentiating PTSD presentations, and tailoring treatments. Treatment includes psychotherapy, primarily CBT, and pharmacotherapy, mainly SSRIs. Patient involvement in care planning and goal setting is essential in a trauma-informed approach.

Strategic interdisciplinary care plans addressing PTSD’s multifaceted nature are vital, including prevention, early intervention, and long-term management, considering both pharmacological and psychological treatments. Ethical considerations include sensitivity, confidentiality, cultural competence, patient autonomy, and informed consent.

Interprofessional communication is key for a holistic approach. Clear, empathetic communication ensures shared understanding and collaboration across disciplines. Care coordination involves aligning team efforts for seamless, continuous patient support, including referrals, information sharing, and a patient-centric healthcare journey. Collaboration with social workers, therapists, and family optimizes social factors for stability in PTSD patients. Effective teamwork and communication are crucial for delivering comprehensive PTSD care, including accurate PTSD differential diagnosis and management.

Review Questions

(Original article includes review questions and references here)

References

1.Miao XR, Chen QB, Wei K, Tao KM, Lu ZJ. Posttraumatic stress disorder: from diagnosis to prevention. Mil Med Res. 2018 Sep 28;5(1):32. [PMC free article: PMC6161419] [PubMed: 30261912]

2.Solomon SD, Canino GJ. Appropriateness of DSM-III-R criteria for posttraumatic stress disorder. Compr Psychiatry. 1990 May-Jun;31(3):227-37. [PubMed: 2340717]

3.Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003388. [PubMed: 17636720]

4.Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD002795. [PMC free article: PMC6993948] [PubMed: 16437445]

5.Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006 Oct;63(10):1158-65. [PubMed: 17015818]

6.Hyland P, Shevlin M, Fyvie C, Karatzias T. Posttraumatic Stress Disorder and Complex Posttraumatic Stress Disorder in DSM-5 and ICD-11: Clinical and Behavioral Correlates. J Trauma Stress. 2018 Apr;31(2):174-180. [PubMed: 29577450]

7.Schuler ER, Boals A. Shattering world assumptions: A prospective view of the impact of adverse events on world assumptions. Psychol Trauma. 2016 May;8(3):259-66. [PubMed: 26214070]

8.Rice TR, Prout T, Cohen J, Russo M, Clements T, Kufferath-Lin T, Joaquin M, Kui T, Kim S, Zaidi A, Hoffman L. Psychodynamic Psychotherapy for Children as a Trauma-Informed Intervention. Psychodyn Psychiatry. 2021 Spring;49(1):73-85. [PubMed: 33635108]

9.Libbrecht K, Quackelbeen J. On the early history of male hysteria and psychic trauma. Charcot’s influence on Freudian thought. J Hist Behav Sci. 1995 Oct;31(4):370-84. [PubMed: 8551015]

10.Spermon D, Darlington Y, Gibney P. Psychodynamic psychotherapy for complex trauma: targets, focus, applications, and outcomes. Psychol Res Behav Manag. 2010;3:119-27. [PMC free article: PMC3218759] [PubMed: 22110335]

11.Streb M, Conway MA, Michael T. Conditioned responses to trauma reminders: How durable are they over time and does memory integration reduce them? J Behav Ther Exp Psychiatry. 2017 Dec;57:88-95. [PubMed: 28477531]

12.Calhoun CD, Stone KJ, Cobb AR, Patterson MW, Danielson CK, Bendezú JJ. The Role of Social Support in Coping with Psychological Trauma: An Integrated Biopsychosocial Model for Posttraumatic Stress Recovery. Psychiatr Q. 2022 Dec;93(4):949-970. [PMC free article: PMC9534006] [PubMed: 36199000]

13.Van Ameringen M, Mancini C, Patterson B, Boyle MH. Post-traumatic stress disorder in Canada. CNS Neurosci Ther. 2008 Fall;14(3):171-81. [PMC free article: PMC6494052] [PubMed: 18801110]

14.Vieweg WV, Julius DA, Fernandez A, Beatty-Brooks M, Hettema JM, Pandurangi AK. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med. 2006 May;119(5):383-90. [PubMed: 16651048]

15.Bisson JI. Post-traumatic stress disorder. BMJ. 2007 Apr 14;334(7597):789-93. [PMC free article: PMC1852007] [PubMed: 17431265]

16.Liebschutz J, Saitz R, Brower V, Keane TM, Lloyd-Travaglini C, Averbuch T, Samet JH. PTSD in urban primary care: high prevalence and low physician recognition. J Gen Intern Med. 2007 Jun;22(6):719-26. [PMC free article: PMC2219859] [PubMed: 17503105]

17.Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol. 2000 Oct;68(5):748-66. [PubMed: 11068961]

18.Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602. [PubMed: 15939837]

19.Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, Karam EG, Meron Ruscio A, Benjet C, Scott K, Atwoli L, Petukhova M, Lim CCW, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Bunting B, Ciutan M, de Girolamo G, Degenhardt L, Gureje O, Haro JM, Huang Y, Kawakami N, Lee S, Navarro-Mateu F, Pennell BE, Piazza M, Sampson N, Ten Have M, Torres Y, Viana MC, Williams D, Xavier M, Kessler RC. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017 Oct;47(13):2260-2274. [PMC free article: PMC6034513] [PubMed: 28385165]

20.Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, Pickering RP, Ruan WJ, Huang B, Grant BF. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016 Aug;51(8):1137-48. [PMC free article: PMC4980174] [PubMed: 27106853]

21.Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):617-27. [PMC free article: PMC2847357] [PubMed: 15939839]

22.Kisely S, Alichniewicz KK, Black EB, Siskind D, Spurling G, Toombs M. The prevalence of depression and anxiety disorders in indigenous people of the Americas: A systematic review and meta-analysis. J Psychiatr Res. 2017 Jan;84:137-152. [PubMed: 27741502]

23.Marshall GN, Schell TL, Elliott MN, Berthold SM, Chun CA. Mental health of Cambodian refugees 2 decades after resettlement in the United States. JAMA. 2005 Aug 03;294(5):571-9. [PubMed: 16077051]

24.Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCahill ME. Posttraumatic stress disorder in the primary care medical setting. Gen Hosp Psychiatry. 2000 Jul-Aug;22(4):261-9. [PubMed: 10936633]

25.Kessler RC, Rose S, Koenen KC, Karam EG, Stang PE, Stein DJ, Heeringa SG, Hill ED, Liberzon I, McLaughlin KA, McLean SA, Pennell BE, Petukhova M, Rosellini AJ, Ruscio AM, Shahly V, Shalev AY, Silove D, Zaslavsky AM, Angermeyer MC, Bromet EJ, de Almeida JM, de Girolamo G, de Jonge P, Demyttenaere K, Florescu SE, Gureje O, Haro JM, Hinkov H, Kawakami N, Kovess-Masfety V, Lee S, Medina-Mora ME, Murphy SD, Navarro-Mateu F, Piazza M, Posada-Villa J, Scott K, Torres Y, Carmen Viana M. How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys. World Psychiatry. 2014 Oct;13(3):265-74. [PMC free article: PMC4219068] [PubMed: 25273300]

26.Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995 Dec;52(12):1048-60. [PubMed: 7492257]

27.Nagamine M, Giltay EJ, Shigemura J, van der Wee NJ, Yamamoto T, Takahashi Y, Saito T, Tanichi M, Koga M, Toda H, Shimizu K, Yoshino A, Vermetten E. Assessment of Factors Associated With Long-term Posttraumatic Stress Symptoms Among 56 388 First Responders After the 2011 Great East Japan Earthquake. JAMA Netw Open. 2020 Sep 01;3(9):e2018339. [PMC free article: PMC7525349] [PubMed: 32990742]

28.Tolin DF, Foa EB. Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. Psychol Bull. 2006 Nov;132(6):959-92. [PubMed: 17073529]

29.Sherin JE, Nemeroff CB. Post-traumatic stress disorder: the neurobiological impact of psychological trauma. Dialogues Clin Neurosci. 2011;13(3):263-78. [PMC free article: PMC3182008] [PubMed: 22034143]

30.Morey RA, Gold AL, LaBar KS, Beall SK, Brown VM, Haswell CC, Nasser JD, Wagner HR, McCarthy G., Mid-Atlantic MIRECC Workgroup. Amygdala volume changes in posttraumatic stress disorder in a large case-controlled veterans group. Arch Gen Psychiatry. 2012 Nov;69(11):1169-78. [PMC free article: PMC3647246] [PubMed: 23117638]

31.Ousdal OT, Milde AM, Hafstad GS, Hodneland E, Dyb G, Craven AR, Melinder A, Endestad T, Hugdahl K. The association of PTSD symptom severity with amygdala nuclei volumes in traumatized youths. Transl Psychiatry. 2020 Aug 17;10(1):288. [PMC free article: PMC7431855] [PubMed: 32807799]

32.Selemon LD, Young KA, Cruz DA, Williamson DE. Frontal Lobe Circuitry in Posttraumatic Stress Disorder. 2019 Jan-Dec/Chronic Stress (Thousand Oaks). 3 [PMC free article: PMC6703563] [PubMed: 31435577]

33.Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL, Gomaa H, Adikey A, Krystal JH. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. Annu Rev Pharmacol Toxicol. 2019 Jan 06;59:171-189. [PMC free article: PMC6326888] [PubMed: 30216745]

34.Blum K, Gondré-Lewis MC, Modestino EJ, Lott L, Baron D, Siwicki D, McLaughlin T, Howeedy A, Krengel MH, Oscar-Berman M, Thanos PK, Elman I, Hauser M, Fried L, Bowirrat A, Badgaiyan RD. Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. Mol Neurobiol. 2019 Nov;56(11):7836-7850. [PMC free article: PMC6815696] [PubMed: 31124077]

35.Tortella-Feliu M, Fullana MA, Pérez-Vigil A, Torres X, Chamorro J, Littarelli SA, Solanes A, Ramella-Cravaro V, Vilar A, González-Parra JA, Andero R, Reichenberg A, Mataix-Cols D, Vieta E, Fusar-Poli P, Ioannidis JPA, Stein MB, Radua J, Fernández de la Cruz L. Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. Neurosci Biobehav Rev. 2019 Dec;107:154-165. [PubMed: 31520677]

36.van der Kolk BA, Pelcovitz D, Roth S, Mandel FS, McFarlane A, Herman JL. Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. Am J Psychiatry. 1996 Jul;153(7 Suppl):83-93. [PubMed: 8659645]

37.Fanai M, Khan MAB. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Acute Stress Disorder. [PubMed: 32809650]

38.Stein DJ, Koenen KC, Friedman MJ, Hill E, McLaughlin KA, Petukhova M, Ruscio AM, Shahly V, Spiegel D, Borges G, Bunting B, Caldas-de-Almeida JM, de Girolamo G, Demyttenaere K, Florescu S, Haro JM, Karam EG, Kovess-Masfety V, Lee S, Matschinger H, Mladenova M, Posada-Villa J, Tachimori H, Viana MC, Kessler RC. Dissociation in posttraumatic stress disorder: evidence from the world mental health surveys. Biol Psychiatry. 2013 Feb 15;73(4):302-12. [PMC free article: PMC3589990] [PubMed: 23059051]

39.Han HR, Miller HN, Nkimbeng M, Budhathoki C, Mikhael T, Rivers E, Gray J, Trimble K, Chow S, Wilson P. Trauma informed interventions: A systematic review. PLoS One. 2021;16(6):e0252747. [PMC free article: PMC8219147] [PubMed: 34157025]

40.Lancaster CL, Teeters JB, Gros DF, Back SE. Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment. J Clin Med. 2016 Nov 22;5(11) [PMC free article: PMC5126802] [PubMed: 27879650]

41.Voss RM, Das JM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 30, 2024. Mental Status Examination. [PubMed: 31536288]

42.Ellis J, Zaretsky A. Assessment and Management of Posttraumatic Stress Disorder. Continuum (Minneap Minn). 2018 Jun;24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):873-892. [PubMed: 29851883]

43.Bourassa KJ, Hendrickson RC, Reger GM, Norr AM. Posttraumatic Stress Disorder Treatment Effects on Cardiovascular Physiology: A Systematic Review and Agenda for Future Research. J Trauma Stress. 2021 Apr;34(2):384-393. [PMC free article: PMC8035275] [PubMed: 33277952]

44.Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015 Dec;28(6):489-98. [PubMed: 26606250]

45.Gold JW, Cardeña E. Convergent validity of three posttraumatic symptoms inventories among adult sexual abuse survivors. J Trauma Stress. 1998 Jan;11(1):173-80. [PubMed: 9479686]

46.Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. [PMC free article: PMC5805662] [PubMed: 28493729]

47.Foa EB, Asnaani A, Zang Y, Capaldi S, Yeh R. Psychometrics of the Child PTSD Symptom Scale for DSM-5 for Trauma-Exposed Children and Adolescents. J Clin Child Adolesc Psychol. 2018 Jan-Feb;47(1):38-46. [PubMed: 28820616]

48.Coventry PA, Meader N, Melton H, Temple M, Dale H, Wright K, Cloitre M, Karatzias T, Bisson J, Roberts NP, Brown JVE, Barbui C, Churchill R, Lovell K, McMillan D, Gilbody S. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020 Aug;17(8):e1003262. [PMC free article: PMC7446790] [PubMed: 32813696]

49.Hamblen JL, Norman SB, Sonis JH, Phelps AJ, Bisson JI, Nunes VD, Megnin-Viggars O, Forbes D, Riggs DS, Schnurr PP. A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update. Psychotherapy (Chic). 2019 Sep;56(3):359-373. [PubMed: 31282712]

50.Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci. 2003 Dec;1008:112-21. [PubMed: 14998877]

51.Zoellner LA, Roy-Byrne PP, Mavissakalian M, Feeny NC. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. Am J Psychiatry. 2019 Apr 01;176(4):287-296. [PubMed: 30336702]

52.Chand SP, Kuckel DP, Huecker MR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 23, 2023. Cognitive Behavior Therapy. [PubMed: 29261869]

53.Markowitz S, Fanselow M. Exposure Therapy for Post-Traumatic Stress Disorder: Factors of Limited Success and Possible Alternative Treatment. Brain Sci. 2020 Mar 13;10(3) [PMC free article: PMC7139336] [PubMed: 32183089]

54.Shapiro F. Eye movement desensitization: a new treatment for post-traumatic stress disorder. J Behav Ther Exp Psychiatry. 1989 Sep;20(3):211-7. [PubMed: 2576656]

55.Shepherd J, Stein K, Milne R. Eye movement desensitization and reprocessing in the treatment of post-traumatic stress disorder: a review of an emerging therapy. Psychol Med. 2000 Jul;30(4):863-71. [PubMed: 11037095]

56.Landin-Romero R, Moreno-Alcazar A, Pagani M, Amann BL. How Does Eye Movement Desensitization and Reprocessing Therapy Work? A Systematic Review on Suggested Mechanisms of Action. Front Psychol. 2018;9:1395. [PMC free article: PMC6106867] [PubMed: 30166975]

57.Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B, Pynoos JD, Zatzick DF, Benedek DM, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, Twemlow SW, Woods S, Yager J., Work Group on ASD and PTSD. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004 Nov;161(11 Suppl):3-31. [PubMed: 15617511]

58.Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006 Jun;26(3):259-67. [PubMed: 16702890]

59.Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, Hart KL, McFall M, Mellman TA, Reist C, Romesser J, Rosenheck R, Shih MC, Stein MB, Swift R, Gleason T, Lu Y, Huang GD. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med. 2018 Feb 08;378(6):507-517. [PubMed: 29414272]

60.Khachatryan D, Groll D, Booij L, Sepehry AA, Schütz CG. Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. Gen Hosp Psychiatry. 2016 Mar-Apr;39:46-52. [PubMed: 26644317]

61.Raskind MA, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Homas D, Hill J, Daniels C, Calohan J, Millard SP, Rohde K, O’Connell J, Pritzl D, Feiszli K, Petrie EC, Gross C, Mayer CL, Freed MC, Engel C, Peskind ER. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013 Sep;170(9):1003-10. [PubMed: 23846759]

62.Villarreal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, Zhai Y, Qualls C. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016 Dec 01;173(12):1205-1212. [PubMed: 27418378]

63.Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002 Oct;159(10):1777-9. [PubMed: 12359687]

64.Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008 Apr;69(4):520-5. [PubMed: 18278987]

65.Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004 Dec;65(12):1601-6. [PubMed: 15641864]

66.Zalta AK, Bravo K, Valdespino-Hayden Z, Pollack MH, Burgess HJ. A placebo-controlled pilot study of a wearable morning bright light treatment for probable PTSD. Depress Anxiety. 2019 Jul;36(7):617-624. [PMC free article: PMC6721597] [PubMed: 30995350]

67.Agarwal V, Sitholey P, Srivastava C. Clinical Practice Guidelines for the management of Dissociative disorders in children and adolescents. Indian J Psychiatry. 2019 Jan;61(Suppl 2):247-253. [PMC free article: PMC6345132] [PubMed: 30745700]

68.Bains N, Abdijadid S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 10, 2023. Major Depressive Disorder. [PubMed: 32644504]

69.O’Donnell ML, Agathos JA, Metcalf O, Gibson K, Lau W. Adjustment Disorder: Current Developments and Future Directions. Int J Environ Res Public Health. 2019 Jul 16;16(14) [PMC free article: PMC6678970] [PubMed: 31315203]

70.Bryant RA, McFarlane AC, Silove D, O’Donnell ML, Forbes D, Creamer M. The Lingering Impact of Resolved PTSD on Subsequent Functioning. Focus (Am Psychiatr Publ). 2023 Jul;21(3):290-295. [PMC free article: PMC10316210] [PubMed: 37404963]

71.Landi G, Pakenham KI, Mattioli E, Crocetti E, Agostini A, Grandi S, Tossani E. Post-traumatic growth in people experiencing high post-traumatic stress during the COVID-19 pandemic: The protective role of psychological flexibility. J Contextual Behav Sci. 2022 Oct;26:44-55. [PMC free article: PMC9420208] [PubMed: 36060527]

72.Dell’Osso L, Lorenzi P, Nardi B, Carmassi C, Carpita B. Post Traumatic Growth (PTG) in the Frame of Traumatic Experiences. Clin Neuropsychiatry. 2022 Dec;19(6):390-393. [PMC free article: PMC9807114] [PubMed: 36627947]

73.Bryngeirsdottir HS, Halldorsdottir S. The challenging journey from trauma to post-traumatic growth: Lived experiences of facilitating and hindering factors. Scand J Caring Sci. 2022 Sep;36(3):752-768. [PMC free article: PMC9543304] [PubMed: 34709685]

74.Wu X, Kaminga AC, Dai W, Deng J, Wang Z, Pan X, Liu A. The prevalence of moderate-to-high posttraumatic growth: A systematic review and meta-analysis. J Affect Disord. 2019 Jan 15;243:408-415. [PubMed: 30268956]

75.Feriante J, Sharma NP. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 2, 2023. Acute and Chronic Mental Health Trauma. [PubMed: 37603622]

76.Solomon SD, Davidson JR. Trauma: prevalence, impairment, service use, and cost. J Clin Psychiatry. 1997;58 Suppl 9:5-11. [PubMed: 9329445]

77.Taft CT, Watkins LE, Stafford J, Street AE, Monson CM. Posttraumatic stress disorder and intimate relationship problems: a meta-analysis. J Consult Clin Psychol. 2011 Feb;79(1):22-33. [PubMed: 21261431]

78.Zatzick D, Roy-Byrne P, Russo J, Rivara F, Droesch R, Wagner A, Dunn C, Jurkovich G, Uehara E, Katon W. A randomized effectiveness trial of stepped collaborative care for acutely injured trauma survivors. Arch Gen Psychiatry. 2004 May;61(5):498-506. [PubMed: 15123495]

79.Wilson JF. Posttraumatic stress disorder needs to be recognized in primary care. Ann Intern Med. 2007 Apr 17;146(8):617-20. [PubMed: 17438329]

Disclosure: Sukhmanjeet Kaur Mann declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.

Disclosure: Tyler Torrico declares no relevant financial relationships with ineligible companies.